Starfish medical icon only logo
Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Global Drug Delivery Challenges Explained

YouTube video thumbnail

In this episode of Bio Break, Nick Allan and Nigel Syrotuck dive into the surprising realities of global drug delivery. While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.

Nigel reflects on a trip to Italy where food sparked thoughts about oral drug delivery. In regions like Italy, pills and tablets are the most common approach. Larger countries also tend to prefer simple, scalable methods such as pills or injections. By contrast, smaller regions may be more open to specialized treatments that require more time or unique handling.

Regional Differences in Drug Delivery

Drug delivery methods are influenced not just by culture, but also by economics, insurance systems, and infrastructure. For example, biosimilars are more readily accepted in some countries depending on reimbursement structures. Meanwhile, large-scale programs — such as vaccine rollouts — highlight how fragile supply chains can be.

Cold Chain and Pandemic Lessons

Certain drugs, including attenuated vaccines, require strict cold chain maintenance. In developing regions, this presents a major challenge. The COVID-19 pandemic underscored this issue when millions of doses expired due to distribution and storage limitations. As Nick and Nigel note, a drug designed for one part of the world may face barriers to adoption in another, depending on the delivery method.

Enjoying Bio Break? Sign up to get new episodes sent to your inbox.

Subscribe to Bio Break
Businessman holding a glowing compliance icon with legal and regulatory symbols, representing REACH SVHC compliance for medical device manufacturers

MPO: REACH SVHC Compliance for Medical Device Makers

Nigel Syrotuck breaks down REACH SVHC compliance for teams working with material suppliers and compliance questionnaires.

Medical Device Design Simulation

MD+DI: Medical Device Simulation Strategy That Works

We examine when computational modelling and simulation, or CM&S, genuinely supports medical device simulation strategy and when it becomes a costly detour.

Transparent medical device prototype surrounded by computational simulation mesh representing modeling and simulation during medical device development.

Building Better Medical Devices Faster: The Strategic Role of CM&S

Many teams still underuse CM&S, often bringing it late in device validation, when key decisions have already been made. That approach leaves much of the value of CM&S untapped.

Biomedical engineer reviewing a thermal simulation of human head tissue on a monitor, color-mapped from warm to cool gradients

Bioheat Transfer in Living Tissue: History, Models, and Engineering Applications

This article traces the Pennes bioheat equation from its 1948 origins to modern multiscale approaches, explaining how engineers select the right level of modelling complexity across device categories.